The subcutaneous injection of amivantamab and hyaluronidase-lpuj was evaluated in PALOMA-3, a randomized, open-label, multicenter, multiregional trial in adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR-exon 19 deletions or exon 21 L858R substitution mutations.…

Read more

fda.gov

FDA approves amivantamab and hyaluronidase-lpuj

On December 17, 2025, the Food and Drug Administration approved amivantamab and hyaluronidase-lpuj (Rybrevant Faspro, Janssen Biotech, Inc.) for subcutaneous injection for adult patients